Anti-USP14 antibody produced in rabbit

USP14 is made up of 494 amino acids containing a 45kDa catalytic domain at its N-terminus. It contains a ubiquitin-like (Ubl) domain at the N-terminus that associates with 19S regulatory particle (RP) 26S proteasome. This binding activates the deubiquitinating activity of the protein.

Ubiquitin carboxyl-terminal hydrolase 14 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

USP14 (ubiquitin specific peptidase 14) gene encodes a protein that belongs to the ubiquitin-specific processing (UBP) family of proteases. It is a proteasome-associated deubiquitinating enzyme (DUB) containing His and Cys catalytic domains. It releases ubiquitin from the proteasome targeted ubiquitinated proteins resulting in regeneration of ubiquitin at the proteasome. It is involved in the degradation of chemokine receptor CXCR4. CXCR4 is required for CXCL12-induced cell chemotaxis and its overexpression leads to cancer and inflammatory and neurodegenerative disorders. Under ER stress, It binds to α, a endoplasmic reticulum (ER) stress receptor, that is involved in unfolded protein response (UPR), a mechanism to control the accumulation of unfolded proteins within the (ER) lumen. Its overexpression leads to ER-associated degradation (ERAD) pathway inhibition.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST77920

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.